Every day in France, 10,000 blood donations are required to treat patients.

A need that is constantly increasing, with an ageing population and with the rise of cancers and other diseases.

The French Blood Establishment (EFS) is the only civil operator of blood transfusions in France ensuring the country to be self-sufficient by fulfilling a public health mission.

But its mission does not end here.

The EFS is conducting innovative medical research, mostly in partnership with Inserm and universities. It carries out research, contributing to scientific and medical progress in the service of patients and in fields related to transfusion activities: laboratory research on blood cells, hematology, cell and tissue therapy, immunology, microbiology and clinical research.

Its expertise is highly recognized.

In 2020, the EFS has 66 patent families in these domains, looking for licensing-out or industrial partnerships. These patents mainly relate to the fields of therapy, particularly cell and tissue therapy and medical devices.

The EFS is also a key player in the French bioproduction system, with its four production platforms of advanced therapy medicinal products (ATMP) in Besançon, Nantes, Créteil and Grenoble, for which it has the status of pharmaceutical establishment.

Through its research and development and the ATMP bioproduction activities, the EFS is at the heart of the French Healthtech ecosystem.